Traws Pharma files tivoxavir marboxil IND application with U.S. FDA

Traws Pharma (TRAW) announced the filing of a U.S. IND application with the U.S. Food and Drug Administration, FDA, for tivoxavir marboxil, TXM, a CAP-dependent endonuclease inhibitor as a single oral tablet administered for the treatment of influenza. “This filing represents an important step towards formal consideration of TXM for influenza therapy and inclusion in the strategic national stockpile,” commented C. David Pauza, PhD, Chief Scientific Officer of Traws Pharma. “Coupled with our ongoing positive interactions with the U.S. Department of Health and Human Services regarding the unique properties of TXM as a broad pan-influenza strain therapeutic, we remain optimistic about the potential inclusion of this agent in the nation’s armamentarium against potential future disease outbreaks.”